- Stocks
- Healthcare
- NYSEAMERICAN: PLX

Price (delayed)

$1.16

Market cap

$85.05M

P/E Ratio

11.6

Dividend/share

N/A

EPS

$0.1

Enterprise value

$84.21M

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to

PLX's price to earnings (P/E) is 23% less than its last 4 quarters average of 14.8

PLX's debt is down by 21% YoY

PLX's net income has soared by 143% year-on-year but it is down by 18% since the previous quarter

PLX's EPS has surged by 133% year-on-year but it is down by 17% since the previous quarter

Protalix BioTherapeutics's quick ratio has decreased by 13% QoQ and by 13% YoY

Protalix BioTherapeutics's equity has decreased by 11% QoQ

What are the main financial stats of PLX

Market
Valuations
Earnings

Shares outstanding

73.32M

Market cap

$85.05M

Enterprise value

$84.21M

Price to earnings (P/E)

11.6

Price to book (P/B)

2.84

Price to sales (P/S)

1.42

EV/EBIT

10.01

EV/EBITDA

8.73

EV/Sales

1.41

Revenue

$59.65M

EBIT

$8.41M

EBITDA

$9.65M

Free cash flow

$4.37M

Per share
Balance sheet
Liquidity

EPS

$0.1

Free cash flow per share

$0.06

Book value per share

$0.41

Revenue per share

$0.82

TBVPS

$1.23

Total assets

$89.83M

Total liabilities

$60.04M

Debt

$26.37M

Equity

$29.79M

Working capital

$20.58M

Debt to equity

0.89

Current ratio

1.38

Quick ratio

0.95

Net debt/EBITDA

-0.09

Margins
Efficiency
Dividend

EBITDA margin

16.2%

Gross margin

62.3%

Net margin

11.5%

Operating margin

13.5%

Return on assets

7.8%

Return on equity

19.5%

Return on invested capital

20%

Return on capital employed

24%

Return on sales

14.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Protalix BioTherapeutics stock price performed over time

Intraday

1.75%

1 week

9.43%

1 month

1.75%

1 year

-35.2%

YTD

-34.83%

QTD

-0.85%

How have Protalix BioTherapeutics's revenue and profit performed over time

Revenue

$59.65M

Gross profit

$37.16M

Operating income

$8.06M

Net income

$6.85M

Gross margin

62.3%

Net margin

11.5%

Protalix BioTherapeutics's operating income has surged by 159% YoY but it has decreased by 23% QoQ

PLX's net income has soared by 143% year-on-year but it is down by 18% since the previous quarter

The operating margin has soared by 141% YoY but it has decreased by 16% from the previous quarter

PLX's net margin has soared by 130% YoY but it is down by 9% from the previous quarter

What is Protalix BioTherapeutics's growth rate over time

What is Protalix BioTherapeutics stock price valuation

P/E

11.6

P/B

2.84

P/S

1.42

EV/EBIT

10.01

EV/EBITDA

8.73

EV/Sales

1.41

PLX's EPS has surged by 133% year-on-year but it is down by 17% since the previous quarter

PLX's price to earnings (P/E) is 23% less than its last 4 quarters average of 14.8

PLX's P/B is 18% below its last 4 quarters average of 3.4

Protalix BioTherapeutics's equity has decreased by 11% QoQ

Protalix BioTherapeutics's revenue has increased by 45% YoY but it has decreased by 9% from the previous quarter

PLX's price to sales (P/S) is 22% lower than its last 4 quarters average of 1.8 and 13% lower than its 5-year quarterly average of 1.6

How efficient is Protalix BioTherapeutics business performance

The return on invested capital has surged by 163% year-on-year but it has declined by 19% since the previous quarter

PLX's return on sales has surged by 143% year-on-year but it is down by 12% since the previous quarter

The ROA has soared by 130% YoY but it has contracted by 24% from the previous quarter

Protalix BioTherapeutics's return on equity has decreased by 34% QoQ

What is PLX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for PLX.

How did Protalix BioTherapeutics financials performed over time

PLX's total assets is 50% greater than its total liabilities

PLX's total assets is up by 35% year-on-year and by 6% since the previous quarter

The company's current ratio fell by 22% YoY and by 10% QoQ

PLX's debt is 11% less than its equity

The debt to equity has dropped by 97% year-on-year but it is up by 14% since the previous quarter

PLX's debt is down by 21% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.